oncology therapeutics News
-
GeneCentric Therapeutics Closes $7.5 Million Series B1 Financing
Durham, N.C., Nov. 8, 2021 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced the closing of an oversubscribed Series B1 financing, which raised $7.5 million. Proceeds will be used to commercialize GeneCentric’s gene signatures and accelerate the growth of its pipeline of predictive response signatures for ...
-
iBio acquires multiple assets of Al drug discovery partner RubrYc
iBio is jockeying for position as a leading player in Al-powered drug discovery while also expanding its immuno-oncology pipeline after closing on the acquisition of multiple assets from its partner, RubrYc Therapeutics. The plant-based drug developer and contract development and manufacturing organization (CDMO) said the deal shores up its ambition to bring immunotherapies to the clinic, ...
By Ibio, Inc.
-
Oncology leads investigation among AseBio’s partners
Despite the pandemic, oncology still being the therapeutic area with the highest level of investigation among AseBio’s partners. Up until 72% of the new cancer treatments are developed thanks to biotechnology and the sector became key, considering that the number of diagnostics decreased due the health crisis according to SEOM’s data. Amadix’ CEO, Rocío Arroyo, ...
By Amadix
-
Ariana announces an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi
Ariana® Pharma a leading Artificial Intelligence drug development company announced today that it has entered into an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi and leading academic partners targeting autoimmune and inflammatory diseases associated with primary immune deficiencies. The ATRACTion project will generate clinical, multi-omic (single cell RNA ...
-
Lynx Biosciences Appoints Sylvaine Cases, Ph.D., as Chief Business Officer
Lynx Biosciences, Inc. (LynxBio®), a biotechnology company generating unparalleled biological insights through integrated multi-omics, today announced the appointment of Sylvaine Cases, Ph.D., as the company's first Chief Business Officer (CBO). Dr. Cases joins LynxBio from Johnson & Johnson, where she was Vice President of Oncology Strategic Partnering. She brings 20 years of combined ...
-
Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ET
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the details of its webcast to discuss updated clinical data from the ongoing monotherapy Phase 1 arm of ...
-
NeoTherma Oncology Raises $6 Million to Advance VectRx to Human Testing
NeoTherma Oncology (NTO), developer of an advanced bioelectric medical device for noninvasive treatment of serious cancers, today announced the closing of a $6 million capital raise. The financing provides the resources to conduct human testing of NTO's VectRx™ thermal oncology treatment platform, designated by FDA as a 'Breakthrough Therapy' for Pancreatic Cancer, expediting patient access ...
-
CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 2:00 p.m. ET. A live webcast of the presentation will be available on the Events and Presentations page of ...
-
GeneCentric Therapeutics Identifies RNA-Based Genomic Markers of Clinical Response in Lung Cancer
The Piedmont Study, a Real-World Data Analysis in Patients Treated with Platinum Doublet Chemotherapy and/or Pembrolizumab, Identifies Predictive Biomarkers for Approved First-Line Treatments in NSCLC DURHAM, N.C.–(BUSINESS WIRE)– GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the completion of its Piedmont ...
-
CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a virtual panel discussion at the Cowen 42nd Annual Healthcare Conference on Monday, March 7, 2022 at 12:50 p.m. ET. A live webcast of the panel will be available on the Events and ...
-
Jubilant Therapeutics Inc. announces US FDA clearance of IND for JBI-778, an Oral, Brain Penetrant and Selective PRMT5 Inhibitor, for treatment of solid tumors with brain metastases and primary brain tumors
Jubilant Therapeutics Inc., a biopharmaceutical Company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced U.S. Food and Drug Administration (US FDA) clearance of the Investigational New Drug application (IND) for JBI-778, an oral, brain penetrant and selective protein arginine methyl transferase 5 (PRMT5) inhibitor, ...
-
NeoTherma Oncology Receives NCI Grant to Advance VectRx MRI Thermometry
NeoTherma Oncology (NTO), developer of an advanced bioelectric medical device for noninvasive treatment of serious cancers, today announced the Company was recently awarded Small Business Innovation Research grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH). This Phase I award provides resources to enable 'Quantifiable Thermal Therapy Using Magnetic ...
-
Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor`s First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology
Regor Therapeutics, a clinical-stage biotech company, announced today authorization from the US Food and Drug Administration (FDA) to proceed with Regor's Phase 1 clinical development plans for RGT-419B. RGT-419B is a new generation CDK2/4/6, small molecule inhibitor with an optimized kinase activity spectrum. It is expected to improve the safety of and combat the resistance to currently ...
-
GeneCentric Therapeutics Collaborates with Labcorp to Develop Novel RNA-Based Oncology Diagnostics
DURHAM, N.C. – October 12, 2021 — GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced a new strategic collaboration with Labcorp, a leading global life sciences company, to develop and commercialize new RNA-based gene signatures as diagnostics for people with cancer. This latest collaboration builds on the ...
-
CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when his current term expires at the company’s next annual meeting of stockholders, which is currently scheduled to be held on June 15, 2022. Dr. Scarlett has served as a member of ...
-
BetaGlue Technologies announces new Board of Directors
BetaGlue (www.betaglue.com), an innovative Italian company in the field of interventional oncology today announced the appointment of its new Board of Directors, composed by investors representatives, independent industry experts and company CEO. New members of the board are Riccardo Palmisano, Company’s Chairman and Geoffroy De Ribains, as independent Board member. Antonino ...
-
Dr. Kiana Aran and Dr. Paul Grint appointed to CRISPR QC Board of Directors
On June 09, 2022, CRISPR QC has announced that Paul Grint and Dr. Kiana Aran have been appointed to the board of directors. "CRISPR QC’s technology is empowering scientists to put the puzzle pieces together of CRISPR editing in a way that was not before possible. Researchers and therapeutics companies can now better design CRISPR components to fit different applications. This insight is ...
By CRISPR QC
-
GeneCentric to Present Initial Clinicogenomic Results from the GARNER High-Risk Non-Muscle Invasive Bladder Cancer Real-World Study
Durham, NC, May 10, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today an upcoming presentation of initial results from the GARNER (Genomic Analysis of high-Risk Non-muscle invasive bladder cancer) real-world study at the 2022 American Urological Association (AUA) Annual Meeting, which is being held in New ...
-
CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Frederick W. Gluck is retiring from its board of directors, effective June 30th, 2022. “It has been an honor to serve on the CytomX board since the company’s founding,” said Frederick W. Gluck. “With a deep and differentiated clinical ...
-
City of Hope and Osel Announce Exclusive License for Intellectual Property on the use of Live Biotherapeutic Product CBM588 for Oncology Therapeutic Applications
City of Hope®, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, and Osel, Inc., a company developing live biotherapeutic products (LBPs) for diseases linked to the disruption of the human microbiome, today announced that City of Hope has granted an exclusive worldwide license to Osel for intellectual property on the novel use ...
By Osel Inc.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you